13.08.2015 • News

GSK Shutters Plant on Bacteria Concerns

GlaxoSmithKline has temporarily shuttered a plant in the US state of North Carolina that produces inhaled medications after routine testing found the bacteria that causes Legionnaire's disease in a self-standing cooling tower.

A spokesperson for the plant near the state capital of Raleigh said testing is conducted every three months, but the company was seeking "more details on whether product has been impacted” and determining the procedure for handling it.

The facility produces inhaled drugs such as the asthma treatment Advair, and also toll manufactures for other pharmaceutical companies. Local officials said they were not aware of any Legionnaire's disease cases associated with the Glaxo plant.

According to reports, the same bacteria was found in cooling tanks in the Bronx borough of New York City earlier this summer, which is believed to have caused 12 deaths from Legionnaires' disease.

The US Centers for Disease Control and Prevention, based in Atlanta, Georgia, said about 8,000 to 18,000 Americans are hospitalized with the illness annually.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read